Cargando…
Case report: Response to endocrine therapy in triple-negative breast cancer metastases with altered hormone receptors
Triple-negative breast cancer refers to breast cancer patients with negative estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2). Metastatic triple-negative breast cancer is predominantly treated with chemotherapy, but later-line treatment remains cha...
Autores principales: | Qin, Ruoyan, Qian, Jie, Shan, Mengjun, Ruan, Guangxin, Yang, Xiaofeng, Wang, Yanwen, Liu, Lingshuang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971810/ https://www.ncbi.nlm.nih.gov/pubmed/36865792 http://dx.doi.org/10.3389/fonc.2023.1023787 |
Ejemplares similares
-
Rewiring of the Endocrine Network in Triple-Negative Breast Cancer
por: Li, Kaixuan, et al.
Publicado: (2022) -
Comprehensive Analysis of the Immunogenomics of Triple-Negative Breast Cancer Brain Metastases From LCCC1419
por: Routh, Eric D., et al.
Publicado: (2022) -
Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study
por: Tolaney, Sara M., et al.
Publicado: (2022) -
Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials
por: El Sayed, Rola, et al.
Publicado: (2019) -
Sacituzumab govitecan and radiotherapy in metastatic, triple-negative, and BRCA-mutant breast cancer patient with active brain metastases: A case report
por: di Mauro, Pierluigi, et al.
Publicado: (2023)